This web only provides the extract of this article. If you want to read the figures and tables, please reference the PDF full text on Blackwell Synergy. Thank you.
- Case Report -
Post-coital gross hematuria: an unusual presentation of benign
prostatic hyperplasia
Yi-Hong Chen, Pei-Yu Lin, Yu-Sheng Cheng, Johnny Shinn-Nan Lin, Yung-Ming Lin
Department of Urology, College of Medicine, National Cheng Kung University, Tainan, Taiwan 704, China
Abstract
Aim: To describe an unusual symptom of benign prostatic hyperplasia (BPH).
Methods: A patient presented to our urology clinic having experienced post-coital gross hematuria for 2 years. He had not experienced lower urinary tract
symptoms (LUTS). A series of examinations were performed to determine the source of
bleeding. Results: The prostate was defined as the active bleeding source responsible for the patient's post-coital hematuria. Endoscopic
fulguration did not alleviate the symptom. The use of dutasteride, a dual inhibitor of
5α-reductase, solved the problem.
Conclusion: This study reports for the first time that post-coital gross hematuria is one of the
clinical presentations of BPH, which can be successfully treated with
5α-reductase inhibitor. (Asian J Androl 2007 Nov; 9: 856_858)
Keywords: prostate; coitus; hematuria
Correspondence to: Dr Yung-Ming Lin, Department of Urology, National Cheng Kung University Hospital, 138 Sheng-Li Road, Tainan,
Taiwan 704, China.
Tel: +886-6-235-3535 ext. 5252 Fax: +886-6-238-3678
E-mail: linym@mail.ncku.edu.tw
Received 2006-09-19 Accepted 2007-07-12
DOI: 10.1111/j.1745-7262.2007.00326.x
1 Introduction
Patients with benign prostatic hyperplasia (BPH) usually complain of bothersome lower urinary tract symptoms
(LUTS), such as urinary frequency, urgency, nocturia, decreased and intermittent force of stream and the sensation
of incomplete bladder emptying [1]. Herein, we describe an unusual presenting symptom of BPH in a man who
presented to having experienced post-coital gross hematuria for 2 years. We describe here the diagnostic modalities,
possible relationship between sexual intercourse and prostatic
bleeding as well as treatment applied to this patient.
2 Case presentation and management
A 61-year-old healthy man with a 2-year history of post-coital painless gross hematuria visited our urology clinic.
The patient's medical history revealed that the patient had experienced neither hematospermia nor urethral bleeding.
He did not have a history of sex-related injury or
LUTS. Gross hematuria occurred after each session of sexual
intercourse, which would persist for 1 to 3 days. Occasionally, acute urinary retention would occur as a result of
blood clot obstruction. The patient has been afraid to partake in sexual activity. A series of examinations, including
coagulation studies, urinalysis, urine culture, urine cytology, prostate specific antigen (PSA), i.v. pyelography, transrectal
ultrasonography and cystourethroscropy (Figure 1A) under local anesthesia did not reveal any abnormality except
BPH. Based on these negative results, cavernosography and spongioso-graphy were performed after artificial erection,
which did not reveal any obvious fistula between corpus
cavernosum/spongiosum and urethra. Repeated cystourethroscopy, during semi-tumescent penile status,
was then performed, showing multiple active bleeders at
the prostate (Figure 1B). Transurethral fulguration was
performed smoothly followed by 16 Fr Foley indwelling
for 3 days; however, the symptom recurred 1 month
later. Given the diagnosis of prostate-related gross
hematuria, the patient was treated with finasteride 5 mg
per day. However, he discontinued therapy at 3 months
because finasteride did not appear to reduce the bleeding
frequency and severity. Dutasteride (0.5 mg per day)
was then given, and the patient was sexually active
1 month later without urinary complaints. The patient
has remained free of symptoms over at least 20 months
during dutasteride therapy.
3 Discussion
Male post-coital gross hematuria is a rare clinical
symptom; however, it can be very frustrating, can
affect the patient emotionally and can reduce the sexual
pleasure as perceive by the patient. From the published
literature, male post-coital gross hematuria can be caused
by different pathological entities, including papillary
adenoma of the prostatic urethra [2, 3], prostatic
utricular papilloma [4], nonvaricose abnormal posterior
urethral vessels [5], urethral polyp [6], arterial fistula [7]
and urethral injury [8]. Based on the negative findings of
cystourethroscopy and lack of genital trauma history,
we confirmed that all of these pathological conditions
did not exist in this patient. Additionally, the normal
findings of hematological study, urine investigation, PSA,
i.v. pyelography, cavernosography and spongiosography
clinically excluded coagulopathy, inflammation,
neoplasm or corporo-urethelial fistulae. In the present case,
the only positive finding was BPH. Together with the
identification of active bleeding sites at the prostate
under a semi-tumescent penis, we believed that the patient's
gross hematuria could be the result of prostate-related
bleeding. Because the patient did not complain of any
LUTS, the findings of the present case highlight
post-coital gross hematuria acting as one of the presenting
symptoms of BPH.
To date, little is known about the relationship
between sexual intercourse and prostatic bleeding. However,
spontaneous prostate bleeding is related to increased
vascularity within hyperplastic prostate tissues and
abnormal friable prostate tissue exposed in the prostatic
urethra [9]. In the present case, a likely explanation for the
patient's symptom is that the bleeding might be derived
from the rupture of friable prostate vessels. During
emission/ejaculation, increased sympathetic tone, contraction
of prostate smooth muscle and closure of the bladder
neck would significantly increase prostatic urethral
pressure, which might lead to the rupture of the friable
vessels of the prostate. Although we are unable to
confirm this mechanism in the present case, the
determination of prostatic vascular density might help in
elucidating the pathophysiology of male coital hematuria in future.
The treatment of prostate-related bleeding includes
expectant management, 5α-reductase inhibitor, endoscopic management, angiographic embolization and open
surgery [10_12]. In the present case, endoscopic
fulguration appeared to have little benefit because the
symptom recurred 1 month later. Although finasteride therapy
has been shown to be an effective method for
BPH-related gross hematuria [10], it seemed to have little effect
on our patient over the 3-month period it was taken. In
a prospective randomized study, patients with
BPH-related gross hematuria were treated with finasteride; the
incidence of hematuria was significantly decreased after
9 months of treatment [11]. This might explain the lack
of efficacy in our patient and stress the need for longer
treatment for resolution. However, dutasteride, a dual
inhibitor of 5α-reductase, rapidly achieved significant
improvement in treating the patient's gross hematuria.
Although the reason behind this difference is yet to be
determined, dutasteride has been shown to result in
greater and consistent suppression of serum
dihydro-testosterone (DHT) at 90%, compared with 70% with
finasteride [13]. Blocking the DHT could lead to
decreased angiogenesis of the prostate and, therefore,
decreased prostatic bleeding [10].
In summary, in addition to LUTS, we report for the
first time that post-coital gross hematuria is one of the
BPH-related symptoms, which could be successfully treated with
5α-reductase inhibitor.
References
1 AUA Practice Guideline Committee. AUA guideline on
management of benign prostatic hyperplasia (2003). Chapter 1:
Diagnosis and treatment recommendations. J Urol 2003; 170:
530_47.
2 Baroudy AC, O'Connell JP. Papillary adenoma of the
prostatic urethra. J Urol 1984; 132: 120_2.
3 Stein AJ, Prioleau PG, Catalona WJ. Adenomatous polyps of
the prostatic urethra: a cause of hematospermia. J Urol 1980;
124: 298_9.
4 Aliabadi H, Cass AS, Gleich P. Utricular papilloma. Urology
1987; 29: 317_8.
5 Cattolica EV. Massive hemospermia: a new etiology and
simplified treatment. J Urol 1982; 128: 151_2.
6 Kumar R, Kesarwani P, Shrivastava DN, Hemal AK.
Post-coital hematuria: presentation of an uncommon case. J Postgrad
Med 2004; 50: 312_3.
7 Tsui KH, Wang LJ, Chang PL, Huang ST, Hsieh ML, Lee SH.
Hematuria from left internal pudendal and obturator arterial
bleeding following sexual intercourse. Arch Androl 2003; 49:
453_5.
8 Cheng YS, Lin JS, Lin YM. Isolated posterior urethral injury:
an unusual complication and presentation following male
coital trauma. Asian J Androl 2006; 8: 379_81.
9 Pareek G, Shevchuk M, Armenakas NA, Vasjovic L, Hochberg
DA, Basillote JB, et al. The effect of finasteride on the
expression of vascular endothelial growth factor and microvessel
density: a possible mechanism for decreased prostatic
bleeding in treated patients. J Urol 2003; 169: 20_3.
10 Miller MI, Puchner PJ. Effects of finasteride on hematuria
associated with benign prostatic hyperplasia: long-term
follow-up. Urology 1998; 51: 237_40.
11 Perimenis P, Gyftopoulos K, Markou S, Barbalias G. Effects
of finasteride and cyproterone acetate on hematuria associated
with benign prostatic hyperplasia: a prospective, randomized,
controlled study. Urology 2002; 59: 373_7.
12 Appleton DS, Sibley GN, Doyle PT. Internal iliac artery
embolisation for the control of severe bladder and prostate
haemorrhage. Br J Urol 1988; 61: 45_7.
13 Clark RV, Hermann DJ, Cunningham GR, Wilson TH, Morrill
BB, Hobbs S. Marked suppression of dihydrotestosterone in
men with benign prostatic hyperplasia by dutasteride, a dual
5alpha-reductase inhibitor. J Clin Endocrinol Metab 2004; 89:
2179_84.
|